Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Recruiting

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

NCT06815029

Conditions: Astrocytoma, Glioblastoma, Glioma, +18 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Recruiting

Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma

NCT07674498

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Institut Jules Bordet Anderlecht, Brussels Capital, Belgium

CHU Saint-Pierre Brussels, Brussels Capital, Belgium

institut roi albert II Woluwe-Saint-Lambert, Brussels Capital, Belgium

View Trial Details

Recruiting

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321

Conditions: ALL, ALL, Childhood, Acute Lymphoblastic Leukemia, +11 more
Locations: University of Chicago Medical Center Chicago, Illinois, United States

The University of Texas Southwestern Medical Center Dallas, Texas, United States

View Trial Details

Recruiting

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

NCT06107738

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Karmanos Cancer Institute Detroit, Michigan, United States

KCI at McLaren Greater Lansing Lansing, Michigan, United States

View Trial Details

Recruiting

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

NCT07559799

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Praxis für interdisziplinäre Onkologie & Hämatologie Freiburg im Breisgau, Germany

View Trial Details

Recruiting

A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

NCT07671378

Conditions: CLL (Chronic Lymphocytic Leukemia), Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Jiangsu Province Hospital Nanjing, Jiangsu, China

View Trial Details

Recruiting

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

NCT06716814

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +16 more
Locations: Sobi Investigational Site Plovdiv, Bulgaria

Sobi Investigational Site Sofia, Bulgaria

Sobi Investigational Site Brest, France

Sobi Investigational Site Bron, France

View all 21 locations

View Trial Details

Recruiting

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Fifth Medical Center of PLA General Hospital ( Site 0005) Beijing, Beijing Municipality, China

Beijing Cancer hospital ( Site 0001) Beijing, Beijing Municipality, China

The First Affiliated Hospital of Xiamen University ( Site 0011) Xiameng, Fujian, China

Sun Yat-Sen University Cancer Center ( Site 0003) Guangzhou, Guangdong, China

View all 15 locations

View Trial Details

Recruiting

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

NCT07575971

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: Chinese PLA General Hospital Beijing, Beijing Municipality, China

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions